Home/Filings/4/0001474064-11-000053
4//SEC Filing

COTTRELL SANDRA 4

Accession 0001474064-11-000053

CIK 0000890465other

Filed

Nov 8, 7:00 PM ET

Accepted

Nov 9, 4:04 PM ET

Size

6.1 KB

Accession

0001474064-11-000053

Insider Transaction Report

Form 4
Period: 2011-11-07
SANDRA COTTRELL
VP, Reg. Affairs & Drug Safety
Transactions
  • Award

    Stock Options

    2011-11-07+8,0008,000 total
    Exercise: $3.34Exp: 2020-02-19Common Stock (8,000 underlying)
Footnotes (1)
  • [F1]On February 19, 2010, the Reporting Person was granted options to purchase shares of Common Stock under the Issuer's 2005 Omnibus Incentive Plan, which are subject to both performance conditions and time-based vesting. On November 7, 2011, the performance criteria for 8,000 of these options had been satisfied because the Issuer's Phase 3 pivotal study of NPSP558 had met the primary efficacy endpoint of a 50 percent or greater reduction in oral calcium supplementation and active vitamin D therapy and a total serum calcium concentration that was normalized or maintained compared to baseline after 24 weeks of treatment. These 8,000 options will vest and become exercisable based on the following vesting schedule: 25% on each of the first four anniversaries of the date of grant.

Issuer

NPS PHARMACEUTICALS INC

CIK 0000890465

Entity typeother

Related Parties

1
  • filerCIK 0001461361

Filing Metadata

Form type
4
Filed
Nov 8, 7:00 PM ET
Accepted
Nov 9, 4:04 PM ET
Size
6.1 KB